An executive order from the White House aims to fast-track approval of psychedelic therapies for mental health, potentially opening new pathways for PTSD care nationwide (policy push). [P]A UT San Antonio researcher is preparing a rapid two-week trial adding MDMA to psychotherapy for soldiers — a military-focused experiment that could rewrite treatment timelines (study). Meanwhile, elected officials and candidates are citing trauma in high-profile controversies, as Maine candidate Graham Platner invoked undiagnosed PTSD to explain past misconduct, fueling debate about responsibility and care (coverage).

A Rhode Island federal judge ordered the government to restart asylum processing after a six-month freeze, a win for applicants whose cases were stalled (ruling). [P]In Europe, leaders agreed in principle to new third-country "return hubs" for rejected asylum seekers — a policy shift that could accelerate deportations and complicate protection standards (EU deal). And closer to home, Latin America is seeing a surge in internally displaced people, underscoring that forced migration increasingly happens without crossing borders (regional crisis).

A Pennsylvania AG report warns that social media pressure is harming teens, while school- and insurer-driven cuts are chipping away at mental-health access for vulnerable kids and families (social media report; Medicaid provider cuts). [P]High-tech developments — from China's commercial brain chip approval to Phase 3 psychedelic trials by ATAI — promise new treatments but raise ethical and access questions (brain chip; psychedelic trial).

The death of former NBA player Brandon Clarke with kratom in his system has renewed scrutiny of the plant's risks and regulatory gap (NYT report). [P]Clinical interest is shifting too: GLP‑1 drugs like semaglutide are being studied for reducing cravings, and the University of Washington is testing brenipatide for alcohol-use disorder — a possible pharmacologic wedge into addiction treatment (semaglutide analysis; brenipatide trial). Harm reduction conversations continue too, with naloxone access and community programs pushed as practical measures beyond arrest-and-count metrics.